ID
13744
Beskrivning
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01034410
Länk
https://clinicaltrials.gov/show/NCT01034410
Nyckelord
Versioner (1)
- 2016-03-02 2016-03-02 -
Rättsinnehavare
CC BY-NC 3.0
Uppladdad den
2 mars 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Acute Myeloid Leukemia NCT01034410
Eligibility Acute Myeloid Leukemia NCT01034410
- StudyEvent: Eligibility
Beskrivning
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Beskrivning
an initial diagnosis of acute promyelocytic leukemia (as defined by french-american-british criteria (bennett 1976))
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0023487
Beskrivning
secondary aml, defined as aml evolving from antecedent hematological disorder or prior exposure to leukemogenic therapy or agent
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0280449
Beskrivning
clinically active cns leukemia
Datatyp
boolean
Alias
- UMLS CUI [1]
- C1332884
Beskrivning
previously received a total cumulative dose of cytarabine > 6g/m2 in the last 6 months
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C0010711
- UMLS CUI [1,2]
- C2986497
Beskrivning
previously received > 1 induction regimen (defined as 1 or 2 cycles of a drug or a drug combination administered as remission induction therapy)
Datatyp
boolean
Alias
- UMLS CUI [1]
- C3179010
Similar models
Eligibility Acute Myeloid Leukemia NCT01034410
- StudyEvent: Eligibility
C0205269 (UMLS CUI [1,2])
C0205269 (UMLS CUI [1,2])
C1982687 (UMLS CUI [2])
C0023467 (UMLS CUI [2,1])
C0277556 (UMLS CUI [2,2])
C2986497 (UMLS CUI [1,2])